AC
NPCE icon

Armistice Capital’s Neuropace NPCE Stock Holding History

Armistice Capital’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.1M Sell
692,000
-100,000
-13% -$1.5M 0.16% 96
2025
Q4 		$12.2M Sell
792,000
-506,000
-39% -$6.77M 0.15% 94
2025
Q3 		$13.4M Buy
1,298,000
+145,665
+13% +$1.37M 0.2% 76
2025
Q2 		$12.8M Sell
1,152,335
-1,279
-0.1% -$16K 0.22% 57
2025
Q1 		$14.2M Buy
1,153,614
+561,000
+95% +$7.02M 0.21% 84
2024
Q4 		$6.63M Buy
592,614
+112,614
+23% +$979K 0.09% 115
2024
Q3 		$3.35M Buy
+480,000
New +$3.51M 0.05% 140

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital's NPCE Position: Q1 2026 in Review

Armistice Capital reduced its Neuropace (NPCE) stake by 13% in Q1 2026, selling an estimated $1.5M and leaving 692,000 shares worth $9.1M. The position accounts for 0.16% of the portfolio, ranked #96.

Armistice Capital first reported a position in NPCE in Q3 2024 and has held it in 7 quarters since. The position peaked at $14.2M in Q1 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Armistice Capital held 692,000 shares of Neuropace worth $9.1M as of Q1 2026.
  • Armistice Capital sold 100,000 Neuropace shares in Q1 2026, an estimated $1.5M.
  • Neuropace made up 0.16% of Armistice Capital's portfolio in Q1 2026, its #96 holding.
  • Armistice Capital first reported a position in Neuropace in Q3 2024 and has held it in 7 quarters since.
  • Armistice Capital's Neuropace position peaked at $14.2M in Q1 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.